Biotec Pharmacon ASA's Subsidiary Announces Results from Animal Study

Biotec Pharmacon ASA announced that its fully owned subsidiary Biotec BetaGlucans AS, has received an interim data report from the fourth animal study in diabetic mice. A goal with this study was to investigate the wound healing efficacy of large scale production batches, also including the first validation batch from June 2012. Included in the study was also experimental dry dressing products wherein SBG (soluble beta -glucan) had been incorporated. The results confirm the finding from the former studies on pilot batches of Woulgan Biogel where the full scale products of Woulgan Biogel showed equal healing efficacy as the already reported pilot batches. The study also showed promising results for the experimental dry dressing product with SBG.